This site is intended for U.S.
residents 18 years of age or older.
This site is intended for U.S.Healthcare Professionals only.

Indications

INDICATIONS

Click for
additional Indication
1 of 4

For Patients Previously Treated with Advanced Non-Small Cell Lung Cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

For Patients with Metastatic Melanoma

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For Previously Treated Patients with Advanced Renal Cell Carcinoma

OPDIVO® (nivolumab) is a prescription medicine used to treat kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other medications.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

OPDIVO® (nivolumab) is a prescription medicine used to treat classical Hodgkin lymphoma (a type of blood cancer that affects white blood cells known as lymphocytes) if your cancer has come back or spread after you had an autologous stem cell transplant (a type of stem cell transplant that uses your own stem cells) and were treated with the drug Adcetris® (brentuximab vedotin) after stem cell transplant.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

OPDIVO (nivolumab)

Go to Healthcare Professional Site

Go to Healthcare Professional Site

Patients, please choose from the conditions below

  • For previously treated patients with advanced Non-Small Cell Lung Cancer
  • For patients with Metastatic Melanoma
  • For previously treated patients with advanced Renal Cell Carcinoma
  • Learn about another condition OPDIVO has been approved to treat
 
 

INDICATIONS

(1 of 4) For Patients Previously Treated with Advanced Non-Small Cell Lung Cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

(2 of 4) For Patients with Metastatic Melanoma

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

(3 of 4) For Previously Treated Patients with Advanced Renal Cell Carcinoma

OPDIVO® (nivolumab) is a prescription medicine used to treat kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other medications.

(4 of 4) For Adults with cHL Whose Cancer has Come
Back or Spread After an Autologous Stem Cell
Transplant Followed by Adcetris® (brentuximab vedotin)

OPDIVO® (nivolumab) is a prescription medicine used to treat classical Hodgkin lymphoma (a type of blood cancer that affects white blood cells known as lymphocytes) if your cancer has come back or spread after you had an autologous stem cell transplant (a type of stem cell transplant that uses your own stem cells) and were treated with the drug Adcetris® (brentuximab vedotin) after stem cell transplant.

It is not known if OPDIVO is safe and effective in children less than 18 years of age.

Important Safety Information for
OPDIVO® (nivolumab) and the
OPDIVO + YERVOY® (ipilimumab) Regimen

OPDIVO is a medicine that may treat your melanoma, lung cancer, kidney cancer, or blood cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.

YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.

Serious side effects may include:

  • Lung problems (pneumonitis). Symptoms of pneumonitis may include: new or worsening cough; chest pain; and shortness of breath.
  • Intestinal problems (colitis) that can lead to tears or holes in your intestine. Signs and symptoms of colitis may include: diarrhea (loose stools) or more bowel movements than usual; blood in your stools or dark, tarry, sticky stools; and severe stomach area (abdomen) pain or tenderness.
  • Liver problems (hepatitis). Signs and symptoms of hepatitis may include: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); drowsiness; dark urine (tea colored); bleeding or bruising more easily than normal; and feeling less hungry than usual.
  • Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas). Signs and symptoms that your hormone glands are not working properly may include: headaches that will not go away or unusual headaches; extreme tiredness; weight gain or weight loss; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness; hair loss; feeling cold; constipation; voice gets deeper; and excessive thirst or lots of urine.
  • Kidney problems, including nephritis and kidney failure. Signs of kidney problems may include: decrease in the amount of urine; blood in your urine; swelling in your ankles; and loss of appetite.
  • Skin Problems. Signs of these problems may include: rash; itching; skin blistering; and ulcers in the mouth or other mucous membranes.
  • Inflammation of the brain (encephalitis). Signs and symptoms of encephalitis may include: headache; fever; tiredness or weakness; confusion; memory problems; sleepiness; seeing or hearing things that are not really there (hallucinations); seizures; and stiff neck.
  • Problems in other organs. Signs of these problems may include: changes in eyesight; severe or persistent muscle or joint pains; and severe muscle weakness.

Additional serious side effects observed during a separate study of YERVOY alone include:

  • Nerve problems that can lead to paralysis. Symptoms of nerve problems may include: unusual weakness of legs, arms, or face; and numbness or tingling in hands or feet.
  • Eye problems. Symptoms may include: blurry vision, double vision, or other vision problems; and eye pain or redness.

Getting medical treatment right away may keep these problems from becoming more serious.

Your healthcare provider will check you for these problems during treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment, if you have severe side effects.

OPDIVO can cause serious side effects, including:

  • Severe infusion reactions. Tell your doctor or nurse right away if you get these symptoms during an infusion of OPDIVO: chills or shaking; itching or rash; flushing; difficulty breathing; dizziness; fever; and feeling like passing out.
  • Complications of stem cell transplant that uses donor stem cells (allogeneic) after treatment with OPDIVO. These complications can be severe and can lead to death. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.

Pregnancy and Nursing:

Tell your healthcare provider if you are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during and for at least 5 months after the last dose of OPDIVO. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant during treatment. Before receiving treatment, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of YERVOY.

Tell your healthcare provider about:

  • Your health problems or concerns if you: have immune system problems such as autoimmune disease, Crohn’s disease, ulcerative colitis, lupus, or sarcoidosis; have had an organ transplant; have lung or breathing problems; have liver problems; or have any other medical conditions.
  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPDIVO, when used in combination with YERVOY include: feeling tired; diarrhea; fever; shortness of breath; rash; nausea; and vomiting. The most common side effects of YERVOY include: tiredness; diarrhea; itching; rash; nausea; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep.

The most common side effects of OPDIVO in people with non-small cell lung cancer include: feeling tired; pain in muscles, bones, and joints; decreased appetite; cough; and constipation.

The most common side effects of OPDIVO in people with renal cell carcinoma include: feeling tired; shortness of breath; pain in the muscles, bones, and joints; decreased appetite; cough; nausea; diarrhea; constipation; and rash.

The most common side effects of OPDIVO in people with classical Hodgkin lymphoma include: feeling tired; upper respiratory tract infection; fever; diarrhea; and cough.

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see U.S. Full Prescribing Information, including Boxed WARNING regarding immune-mediated side effects, and Medication Guide for YERVOY.

Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO.

Information provided in this website is not a substitute for talking with your healthcare professional. Your healthcare professional is the best source of information about your disease.

All individuals depicted are models used for illustrative purposes only.

 

You are about to leave this Bristol-Myers Squibb
Company site. You are being redirected to another
Bristol-Myers Squibb Company site.

Would you like to leave this site?

 

Yes

No

 

You Are Being Redirected to Bristol-Myers Squibb
Medical Information Online

Would you like to leave this site?

Yes

No

 

You are now leaving this Bristol-Myers Squibb site.

This Internet site may provide links or references to other sites.
BMS has no responsibility for the content of such other sites and
is not liable for any damages or injury arising from that content.
Any links to other sites are provided merely as a convenience to the
users of this Internet site.